英国生物银行房颤患者早期节律控制的适用性分析
基于英国生物银行人群数据,按EAST-AFNET4标准评估房颤患者早期节律控制适用性。新发房颤者80.9%符合条件,但仅9.02%接受早期节律控制。全队列主要复合终点风险降低(HR 0.82),倾向匹配后无显著差异(HR 0.87)。
要点
- 约80%新发房颤患者符合早期节律控制条件。
- 实际接受早期节律控制者仅占9.02%。
- 早期节律控制安全性良好,全队列主要终点风险降低。
核心结论
- 英国人群中约80%房颤患者符合早期节律控制条件,但实际接受治疗比例低。
- 早期节律控制在常规诊疗中安全,全队列显示主要终点风险降低,但倾向匹配后无显著差异。
研究设计与样本
- 基于英国生物银行人群的观察性研究,按EAST-AFNET4纳入/排除标准评估房颤患者。
- 将符合条件者的治疗分为早期节律控制(抗心律失常药物或房颤消融)与常规治疗,比较全队列及倾向匹配数据集中的疗效与安全性终点。
主要发现
- 符合条件者较不符合者年龄更大(70岁 vs 63岁),女性比例更高(42% vs 21%)。
- 9004例有完整初级保健数据者中,874例(9.02%)接受早期节律控制。
- 全队列中早期节律控制组主要复合终点(心血管死亡、卒中/短暂性脑缺血发作、心衰或急性冠脉综合征住院)发生率更低(HR 0.82,95%CI 0.71-0.94,p=0.005)。
- 倾向评分匹配分析中,早期节律控制未显著降低主要终点(HR 0.87,95%CI 0.72-1.04,p=0.124)。
关键数值与推荐
- EAST-AFNET4主要终点为心血管死亡、卒中/短暂性脑缺血发作、心衰或急性冠脉综合征住院的复合终点。
- 全队列主要终点HR 0.82(95%CI 0.71-0.94,p=0.005),倾向匹配后HR 0.87(95%CI 0.72-1.04,p=0.124)。
临床怎么用
- 在常规诊疗中可参考EAST-AFNET4标准识别适合早期节律控制的房颤患者。
- 早期节律控制(抗心律失常药物或消融)在常规实践中安全性良好。
- 实际治疗率低,提示需加强符合条件患者的早期节律控制实施。
局限性
- 观察性研究设计,存在残余混杂可能。
- 仅部分参与者有完整初级保健数据,治疗分类可能不完整。
- 倾向匹配后疗效不显著,需谨慎解读全队列结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Early Treatment of Atrial Fibrillation for Stroke Prevention (EAST-AFNET4) trial showed a clinical benefit of early rhythm-control therapy in patients with recently diagnosed atrial fibrillation (AF). The generalisability of the results in the general population is not known. METHODS: Participants in the population-based UK Biobank were assessed for eligibility based on the EAST-AFNET4 inclusion/exclusion criteria. Treatment of all eligible participants was classified as early rhythm-control (antiarrhythmic drug therapy or AF ablation) or usual care. To assess treatment effects, primary care data and Hospital Episode Statistics were merged with UK Biobank data.Efficacy and safety outcomes were compared between groups in the entire cohort and in a propensity-matched data set. RESULTS: AF was present in 35 526/502 493 (7.1%) participants, including 8340 (988 with AF <1 year) with AF at enrolment and 27 186 with incident AF during follow-up. Most participants (22 003/27 186; 80.9%) with incident AF were eligible for early rhythm-control.Eligible participants were older (70 years vs 63 years) and more likely to be female (42% vs 21%) compared with ineligible patients. Of 9004 participants with full primary care data, 874 (9.02%) received early rhythm-control. Safety outcomes were not different between patients receiving early rhythm-control and controls. The primary outcome of EAST-AFNET 4, a composite of cardiovascular death, stroke/transient ischaemic attack and hospitalisation for heart failure or acute coronary syndrome occurred less often in participants receiving early rhythm-control compared with controls in the entire cohort (HR 0.82, 95% CI 0.71 to 0.94, p=0.005). In the propensity-score matched analysis, early rhythm-control did not significantly decrease of the primary outcome compared with usual care (HR 0.87, 95% CI 0.72 to 1.04, p=0.124). CONCLUSION: Around 80% of participants diagnosed with AF in the UK population are eligible for early rhythm-control. Early rhythm-control therapy was safe in routine care.
引用
- Kany, Cardoso, Bravo, et al. Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank. Heart. 2022. PMID: 35835543. doi:10.1136/heartjnl-2022-321196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。